Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 19/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154229 | 0.92 | PTPN11 (0.44) | PTPN11EGFRKCNH2 | |
| SCHEMBL23186864 | 0.86 | PTPN11 (0.39) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514515 | 0.83 | PTPN11 (0.41) | PTPN11EGFRKCNH2KDM4EALDH1A1 | |
| SCHEMBL25514875 | 0.80 | PTPN11 (0.43) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514526 | 0.79 | PTPN11 (0.41) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514651 | 0.77 | PTPN11 (0.55) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514338 | 0.76 | PTPN11 (0.60) | PTPN11EGFRKCNH2 | |
| SCHEMBL23186778 | 0.76 | PTPN11 (0.44) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514784 | 0.76 | PTPN11 (0.39) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514336 | 0.75 | PTPN11 (0.62) | PTPN11EGFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885EGFR 2069/4885KCNH2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.